免疫疗法再挑战对大多数在初始ipilimumab + Nivolumab响应后晚期进展的患者有效
Ethan Trim1, Anita Giobbie-Hurder1,2, Tamara A Sussman1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Pigment cell & melanoma research
|June 19, 2025
概括
在Ipilimumab+nivolumab组合治疗与免疫检查点抑制 (ICB) 后进展的晚期黑色素瘤患者的复试可以带来临床益处,特别是在皮肤黑色素瘤亚型中.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 黑色素瘤研究 黑色素瘤研究
背景情况:
- 伊皮利穆马布 + 尼沃卢穆马布联合治疗在晚期黑色素瘤中提供了持久的临床益处.
- 治疗结束后的晚期进展发生在一小部分患者中.
- 对于晚期进展的后续免疫疗法选择的有效性在很大程度上是未知的.
研究的目的:
- 为了评估复发性黑色素瘤患者在Ipilimumab + nivolumab与免疫检查点抑制 (ICB) 后经历晚期进展的再挑战患者的疗效.
主要方法:
- 对230名先进黑色素瘤患者进行了回顾性分析,这些患者接受了第一线伊皮利马布+尼沃马布治疗.
- 对19名晚期进展 (14人治疗结束后) 患者的评估.
- 在10名患者的ICB重试后,评估临床益处 (病情稳定或更好).
主要成果:
- 在10名患者中,有8名 (80%) 患有晚期进展的患者在ICB重试时获得了临床益处 (SD或更好).
- 皮肤黑色素瘤患者显示好处,而粘膜黑色素瘤患者没有.
- 对重新挑战的反应大多是稳定的疾病和相对短暂的.
结论:
- 免疫检查点抑制再挑战是一种可行的策略,用于患有晚期黑色素瘤的患者经历后期进展后,伊皮利马布 + 尼沃马布.
- 皮肤黑色素瘤患者似乎比粘膜黑色素瘤患者更受益于重新挑战.
- 虽然可以实现反应,但它们往往是有限的持续时间.
关键词:
免疫检查点抑制剂 免疫检查点抑制剂这里是 ipilimumab 的所在地.黑色素瘤是一种黑色素瘤.这就是尼沃卢马布 (nivolumab).复发性 复发性 复发性回顾性研究是回顾性研究.挽救疗法是一种救援疗法.更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.7K
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.8K
相关概念视频
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Cytotoxic T Cells-mediated Immune Response
2.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.5K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Immunological Memory
6.2K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
6.2K
